GBR 1302

Drug Profile

GBR 1302

Alternative Names: GBR-1302; HER2xCD3 bispecific antibody - Glenmark

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 03 Jan 2017 US FDA approves IND application for GBR 1302 in HER2 positive cancer
  • 04 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer were presented at European Society of Medical Oncology Symposium (ESMO-2016)
  • 01 May 2016 Phase-I clinical trials in HER2 positive Cancer in Germany (Parenteral) (NCT02829372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top